Michael Staudigl
About Michael Staudigl
Michael Staudigl is the Medical Director of Immunology and Fibrosis in Dermatology and Rheumatology at Bristol Myers Squibb in München, Bayern, Deutschland. He has over a decade of medical experience, specializing in dermatology, rheumatology, and oncology, with a focus on immunology, fibrosis, and CAR-T cell therapy.
Current Role at Bristol Myers Squibb
Michael Staudigl currently serves as the Medical Director of Immunology and Fibrosis, specializing in Dermatology and Rheumatology, at Bristol Myers Squibb in München, Bayern, Deutschland. He is responsible for leading medical initiatives in these areas and ensuring the strategic alignment of medical projects with company goals.
Previous Roles at Bristol Myers Squibb
Prior to his current role, Michael Staudigl worked as a Senior Medical Advisor Oncology at Bristol Myers Squibb from 2019 to 2021. Before that, he held the position of Medical Advisor Oncology from 2017 to 2018. His progression at the company reflects his expertise in oncology and his ability to take on increasingly complex responsibilities.
Experience in Pediatric Care
Michael Staudigl has significant experience in pediatric care, having worked at Dr. von Haunersches Kinderspital der LMU München. He served as Assistenzarzt Pädiatrie from 2010 to 2016 and later as Facharzt für Kinder- und Jugendheilkunde from 2016 to 2017. This background provided him with a strong foundation in medical practice and patient care.
Educational Background
Michael Staudigl completed his medical studies at Ludwig-Maximilians Universität München, where he earned his medical degree (Dr. med.). His academic training provided him with the knowledge base and skills required for his diverse roles in the medical field, spanning pediatrics, oncology, dermatology, and rheumatology.
Specialization and Research Focus
Specializing in dermatology and rheumatology, Michael Staudigl has a strong focus on immunology and fibrosis. His research interests include CAR-T cell therapy and personalized cancer medicine. He is actively involved in innovative research aimed at developing new treatment options for severe blood cancers, contributing to the advancement of medical science in these areas.